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ABSTRACT A role for adenosine in immunosenes-
cence was investigated in T cells from older (>65 yr)
and younger (24–45 yr) healthy humans. Adenosine
concentrations in cultures of activated T cells were
significantly higher (P<0.0001) for older (14547 nM,
meanSD) than younger (585.5 nM) subjects. Expres-
sion of the activation coreceptor CD28 was suppressed
significantly by 0.1 to 1 M exogenous adenosine, with
greater effects of 1 M (P<0.01) on T cells of younger
(mean suppression of 67 and 65% for CD4 and CD8 T
cells, respectively) than older (means of 42 and 46%)
subjects. T-cell chemotaxis to CCL21 was suppressed
significantly by 0.3 and 1 M exogenous adenosine,
with mean maximum decreases of 39 and 49%, respec-
tively, for younger subjects and 28 and 31% for older
subjects. Generation of IL-2 and IFN- by T cells of
younger and older subjects was suppressed substan-
tially only at adenosine levels of 3 M or higher. Lower
baseline expression of CD28 and chemotaxis to CCL21
and S1P for T cells from older subjects attributable to
endogenous adenosine were reversed completely by
two different A2A adenosine receptor antagonists with-
out affecting T cells of younger subjects. Adenosine is
an endogenous T-cell immunosuppressor in older
humans, and A2A antagonists reverse adenosine-in-
duced T-cell deficiencies of aging.—Hesdorffer,
H. S., Malchinkhuu, E., Biragyn, A., Mabrouk, O. S.,
Kennedy, R. T., Madara, K., Taub, D. D., Longo,
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Adenosine is a prominent mediator in many organ
systems, in which the specific cellular effects are regu-
lated by control of local tissue concentrations and levels
of expression of one or more of its G-protein-coupled
receptors. T cells generate adenosine through the
sequential conversion of ATP to AMP by the ecto-
nucleoside triphosphate diphosphohydrolase-1 activity
of CD39 and AMP to adenosine by the ecto-5-nucleoti-
dase function of CD73 (1, 2). Of the T-cell subsets, only
Foxp3 CD4 T-regulatory (Treg) cells express both
CD39 and CD73 (3). CD39 also is expressed by memory
CD4 T cells of the Th1, Th2, and Th17 types, which lack
Treg functions and do not bear CD73 (4). CD73 is also
expressed by most CD8 T cells and activated CD4
effector T cells, lacking Treg functions, and is especially
prominent on tissue-infiltrating T cells as a result of its
mediation of their binding to vascular and lymphatic
endothelium in inflamed tissues (5–7). Thus, it is clear
that optimal adenosine production by T cells other
than Tregs requires the concerted participation of both
effector and memory sets. Levels of adenosine in blood
are normally 100 to 300 nM, and in microdialysates of
murine extracellular fluid, levels were 30  5 nM
(meanse) for normal subcutaneous tissues and 0.2 to
2.4 M for subcutaneous murine and human tumors
(8). Concentrations of adenosine in lymphoid tissues
normally and during immune responses have not been
determined, but most in vitro studies of its effects have
employed 5 to 25 M adenosine (9–12). Human and
mouse T cells express predominantly the A2A subtype of
adenosine receptor, with lower abundance of the A2B
and A3 subtypes, and little of the A1 subtype (13, 14).
The levels of the A2A receptor, and to a lesser extent,
the A2B and A3 subtypes, on T cells are increased nearly
10-fold by immunological stimulation (14). The func-
tional dominance of T-cell A2A receptors is amplified
greatly by their 100-fold greater affinity for adenosine
than the A2B and A3 subtypes (13). Although quite
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preliminary, existing data for mouse T cells suggest that
inhibition by adenosine of cytokine generation and
expression of some cell-surface antigens may be prefer-
entially transduced by A2A receptors, whereas adeno-
sine prevention of proliferation may be largely signaled
by A3 receptors (13).
T-cell immune effects of adenosine often are consid-
ered in 2 timeframes because regulation of T-cell
trafficking was observed predominantly acutely, and
both reduction of telomerase activity and decreases in
expression of CD28 by human CD8 T cells have re-
quired chronic adenosine exposure. Single additions of
5 to 25 M adenosine to mouse or human T cells
suppressed proliferation and the generation of IL-2,
IFN-, and IL-4 acutely, and multiple additions of the
same concentrations of adenosine to T-cell cultures
over several weeks diminished IL-2 gene transcription
(9–12). Generation of adenosine was necessary for
optimal Foxp3Treg-cell suppressive activity in short-
term cultures (3). In the initial 24 h of mouse or
human T-cell responses, adenosine reduced activa-
tion-induced apoptosis acting through the A2A aden-
osine receptor, but its ability to influence survival for
longer periods remains controversial (15). Adeno-
sine at the same 5 to 25 M levels rapidly decreased
the expression of CD28 in murine mixed T cells, but
much longer incubations were needed for the same
effects in human CD8 T cells (10, 12).
The most complex immune activity of the adenosine
mediator system appears to be acute regulation of
T-cell trafficking in afferent lymphatics. The T cells in
afferent lymph and afferent lymphatic endothelium,
but not efferent lymphatic endothelium, both express
high levels of CD73, which presumably generates aden-
osine as well as enhances T-cell adhesiveness (7). In two
different experimental systems, deletion of CD73 on
lymphocytes gave opposite results of decreased migra-
tion to draining lymph nodes by 50% in one and no
difference in lymphocyte trafficking in the other (6, 7).
Nonetheless, the importance of adenosine as a primary
mediator capable of decreasing T-cell movement in
afferent lymphatics was demonstrated by the striking
suppression of their entry into lymph nodes in CD73-
deficient mice when a selective adenosine agonist was
administered to restore the usual level of adenosine
receptor signaling (6).
Chronic effects of repeated additions of adenosine
on human CD8 T cells together resembled replicative
senescence, including decreased proliferative poten-
tial, reduced IL-2 gene expression, diminished surface
levels of CD28, and lower telomerase activity (12).
Development of these T-cell characteristics of an aging
immune system required exposure of cultured human
T cells to 10 M adenosine for 70 d or longer. The
purpose of the present study of immunosenescence was
to establish the levels of endogenous adenosine usually
present in the extracellular fluid of lymphoid tissue T
cells in older and younger subjects and to identify
differences between human T cells from older and
younger subjects in their functional responses to these
physiological concentrations of adenosine.
MATERIALS AND METHODS
Subject selection and study design
Each of 18 healthy subjects aged 65 yr or older was studied
concurrently with a healthy younger control of age 24 to 45
yr, with older to younger matching based on sex and race.
There were 13 healthy younger controls, of whom 5 served as
controls for 2 older subjects. Subjects were recruited from the
Clinical Research Unit and Baltimore Longitudinal Study of
Aging populations of the U.S. National Institute on Aging and
from long-term care and ambulatory populations of the
Jewish Home of San Francisco. Every participant was in-
formed of the procedures and potential risks of donating 60
ml of venous blood before signing a consent form, and the
study protocol was approved by the committees for human
research at the two institutions. None of the subjects was
receiving any immunoactive drug or hormone. The mean 
sd age of the older subjects was 77  6.6 yr with a range of
65–88 yr; 11 were Caucasian, 5 were African-American, and 2
were Asian. The mean  sd age of the older women (n9)
was 75  7.5 yr with a range of 65 to 85 yr. The mean  sd age
of the older men (n9) was 78  5.6 yr with a range of 72 to
88 yr. The mean  sd age of the younger subjects was 37 
7.8 yr with a range of 24 to 45 yr; 9 were Caucasian, 2 were
African-American, and 2 were Asian. The mean  sd age of
the younger women (n5) was 35  9.3 yr with a range of 26
to 45 yr. The mean  sd age of the younger men (n8) was
37  7.1 yr with a range of 24 to 45 yr. There were no
significant group age differences between men and women in
either age group.
Chemicals
The A2A receptor antagonists ANR94 and SCH58261 and the
A2A receptor agonist CGS21680 hydrochloride (Tocris Biosci-
ences, Ellisville, MO, USA), the A3 receptor antagonist 2-phenyl-
amino-N6-endo-norbornyladenine (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), the ADA inhibitor erythro-9-(2-hydroxy-
3-nonyl)-adenine hydrochloride (EHNA), adenosine, sphin-
gosine 1-phosphate (S1P), and recrystallized bovine serum albu-
min (Sigma Chemicals, St. Louis, MO,USA) were obtained from
the designated suppliers.
Isolation of T cells
Heparinized blood was diluted 1:1 (v:v) with calcium- and
magnesium-free PBS, and 30-ml portions were centrifuged on
10-ml cushions of Ficoll-Paque (GE Healthcare Life Sciences,
Pittsburgh, PA, USA) for 30 min at 400 g to resolve mixed
mononuclear leukocytes at the interface from other blood
cells, as described previously (16). The total population of T
cells was obtained at 96% purity by 2 cycles of immunomag-
netic depletion of all non-T-cell mononuclear leukocytes with
an antibody cocktail negative selection kit (Miltenyi Biotec,
Auburn, CA, USA).
Determination of the concentrations of adenosine and
inosine in T-cell culture supernates
Three sets of duplicate suspensions of 1 	 106 T cells in 1 ml
of RPMI 1640 with 10% fetal bovine plasma, 100 U/ml of
penicillin G, and 50 g/ml of streptomycin (complete RPMI)
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were incubated in 24-well plates without (1 set) and after (2
sets) precoating with 1 g each of anti-human CD3 plus
anti-human CD28 antibodies, as described previously (17). At
24 h, the T cells were washed twice and resuspended in
plasma-free RPMI for an additional 24 h of incubation in
original wells. The ADA inhibitor EHNA was added to one
duplicate set of antibody-precoated duplicate wells at 10 M.
Plates then were centrifuged at 3000 g, and the supernates
were harvested, passed through 0.22-m-pore filters (Millex;
Sigma-Aldrich), and stored at 
80°C. To quantify adenosine
and inosine, 9-l aliquots of each T-cell supernatant were
injected in triplicate into an ultra-high-pressure liquid chro-
matography (UPLC) mass spectrometer. The UPLC appara-
tus with a nanoAcquity autosampler (Waters, Waltham, MA,
USA) was fitted with a Waters HSS T3 C18 column (1	100
mm, 1.8 m) coupled to a Waters/Micromass Quattro Ultima
II triple-quadrupole mass spectrometer in positive mode,
operating with multiple reaction monitoring. Quadrupole
settings were capillary voltage equal to 3 kV, source temper-
ature equal to 140°C, cone voltage equal to 35 kV, and
collision energy equal to 20 eV. The elution program was
equilibration prior to injection in 100% mobile phase A (10
mM ammonium formate in 0.15% formic acid), a rapid step
from 100% A to 77% A:23% B (acetonitrile) that was contin-
ued for 2 min, and a rapid step back to 100% A. Calibration
was performed with a 1 nM to 1 M 5-point standard curve.
Flow-cytometric analyses of T-cell expression of surface
protein antigens
T cells were harvested, washed twice in flow-cytometry buffer
(PBS with 1 g/100 ml of BSA and 0.1 g/100 ml of sodium
azide), incubated 10 min at room temperature in human Fc
receptor blocking solution (Biolegend, San Diego, CA, USA)
diluted 1:20 with flow-cytometry buffer, and incubated for 30
min at 4°C in the dark with multiple fluorescently labeled
antibodies at recommended dilutions in flow-cytometry buf-
fer. After fixation in 1% paraformaldehyde and washing in
flow-cytometry buffer, T-cell labeling was examined in a
FACScalibur system equipped with CellQuest software (BD-
Pharmingen, San Diego, CA, USA), as described previously
(18). Antibodies and their sources were mouse anti-human
CD8-allophycocyanin (APC) and mouse anti-human CD39-
Alexa Fluor 488 (Invitrogen, Carlsbad, CA, USA), mouse
anti-human CD4-APC and mouse anti-human CD73-phyco-
erythrin (PE; clones OKT4 and AD2, respectively; Biolegend),
and anti-human CD28-PE (clone CD28.2; R&D Systems, Min-
neapolis, MN, USA). A mouse monoclonal IgG2a anti-human
adenosine A2A receptor antibody (Life Span Biosciences,
Seattle, WA, USA) was labeled with PE using a standard kit
(Lightning-Link PE-Cy5.5 Tandem conjugation kit; Innova
Biosciences, Cambridge, UK).
Cytokine ELISAs
The concentrations of IL-2 and IFN- in duplicate aliquots of
T-cell supernates were quantified at respective dilutions of 1:5
and 1:300 with colorimetric ELISAs (MiniKits from Thermo
Scientific-Pierce Biotechnology, Rockford, IL, USA). Color
intensity was determined in a VersaMax Microplate Reader
(Sunnyvale, CA, USA).
Quantification of T-cell chemotaxis
Transwell plate permeable upper inserts with a 5-m-pore
filter (Corning Life Sciences, Lowell, MA, USA) were prein-
cubated overnight at 4°C in human type IV collagen, washed,
and dried, as described previously (19). Each of duplicate
upper inserts received 1 	 106 T cells in 0.1 ml of RPMI 1640
with 10% dextran- and charcoal-extracted FBS (lipid-depleted
FBS; Univeristy of California–San Francisco Cell Culture
facility) and was placed in the plate over 0.6 ml of RPMI-lipid-
depleted FBS without (control) or with 50 nM CCL21 (Pep-
rotech, Rocky Hill, NJ, USA) or 100 nM S1P in its lower
compartment. Some suspensions of T cells were preincubated
for 10 min at room temperature with adenosine, the ADA
inhibitor EHNA, the A2A receptor agonist CGS21680, or the
A2A receptor antagonists SCH58261 or ANR94 prior to
loading in the chemotactic chamber. After incubation at
37°C for 4 h, the number of T cells in each lower
compartment was determined by microscopic counting
and expressed as a percentage of the initial number added
to the upper insert.
Statistical evaluations
The significance of differences between mean values in any
series of studies was calculated by a 2-sample t test or with a
nonparametric method if data distribution was not normal
(GraphPad Software, La Jolla, CA, USA).
RESULTS
Human T-cell generation of adenosine
The capacity of human blood T cells from healthy older
and younger donors to produce adenosine was exam-
ined using a mixed T-cell population, which expresses
the enzymes CD39 and CD73 required to convert ATP
to adenosine. Adenosine concentrations in the culture
medium of T cells activated by an antigen receptor-
TABLE 1. Greater generation of adenosine by T cells of older healthy than younger healthy subjects
Age group Subjects (n) T-cell activation ADA inhibitor Adenosine concentration (nM) Inosine concentration (nM)
Old 9  
 145  47** 100  41*
Young 8  
 58  5.5 52  24
Old 6   333  196 224  193
Young 5   344  494 187  286
Old 3 
 
 18  4.4 21  3.6
Young 3 
 
 13  1.7 20  5.5
Adenosine and inosine concentrations are standardized for 106 mixed T cells/ml; values are means  sd. Studies were conducted in
duplicate, and supernates were assayed in triplicate. Subjects in the bottom 4 rows are subsets of those studied for the top 2 rows. The ADA
inhibitor was 10 M EHNA. A 2-sample t test was used to compare results for T cells of older subjects with those of younger subjects, except
for values with EHNA, where distribution was non-normal and comparison was with a Mann-Whitney nonparametric test. *P  0.0108; **P 
0.0001.
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dependent mechanism were substantially higher than
those of unactivated T cells and were very significantly
higher for older than younger subjects (Table 1).
Concentrations of inosine, the product of adenosine
deaminase biodegradation of adenosine, also were sig-
nificantly higher in culture medium of activated T cells
from older than younger subjects. When EHNA was
introduced to inhibit adenosine deaminase, adenosine
concentrations were higher, but results were non-nor-
mally distributed with greater scatter, and there was no
difference between mean values for activated T cells of
old and young subjects. These findings indicate that the
range of adenosine concentrations most relevant to
investigations of effects on T-cell immune functions is
0.1 to 1 M rather than the previously studied range of
5 to 25 M (9–12).
Effects of adenosine on human T-cell production of
cytokines
A single addition of 0.3 M adenosine at the beginning
of antigen receptor stimulation of T cells from older
and younger subjects failed to suppress generation of
IL-2 significantly (Fig. 1). In contrast, one addition of
an optimally effective concentration of the adenosine
deaminase inhibitor EHNA at the beginning of the
same activating incubation very significantly suppressed
generation of IL-2 by T cells from older and younger
subjects. As adenosine deaminase inhibition is ex-
pected to establish a medium concentration of endog-
enous adenosine near 0.3 M (Table 1), this result
suggests that a sustained level of adenosine has far
greater effects on T-cell cytokine generation than those
attained by a transient pulse of the same or higher
concentrations. This possibility is supported by a find-
ing that single additions of 1 and 3 M adenosine did
not materially reduce the levels of IL-2 or IFN-
achieved by activated T cells from older or younger
subjects (Fig. 1). Adenosine (10 M) in a single addi-
tion reduced IL-2 and IFN- production by activated T
cells from older and younger subjects, and the decrease
in IL-2 level was similar to that attained by the approx-
imate sustained concentration of 0.3 M adenosine
from adenosine deaminase inhibition (Fig. 1).
To further elucidate the possible importance of
persistent adenosine levels in regulation of human
T-cell cytokine production, the effects of multiple ad-
ditions of exogenous adenosine were compared to
those of the elevated adenosine level attained by inhi-
bition of adenosine deaminase. Multiple additions of 3
M adenosine significantly reduced the levels of IL-2
and IFN- achieved by activated T cells from older and
younger subjects by a mean of 43 to 65% (Fig. 2),
whereas it had suppressed by only 24% or less after a
single addition (Fig. 1). Multiple additions of 10 M
adenosine or EHNA suppressed the production of IL-2
and IFN- to the same very significant extent as had a
single addition. In the presence of normal levels of
adenosine deaminase activity, thus, it appears that the
usually expected concentrations of endogenous aden-
osine would have only modest regulatory effects on
cytokine production by T cells of younger or older
humans.
As the T-cell activation required to increase medium
levels of adenosine also may evoke generation of other
immunoregulatory factors, it is only possible to distin-
guish specific effects of adenosine by the application of
selective pharmacological probes of the T-cell adenosine
system. To examine the role of endogenous adenosine as
a suppressor of IL-2 generation, the SCH58261 antagonist
of A2A adenosine receptors that predominate in T cells
(13–15) was added to cultures of mixed T cells from 3
older and 3 younger healthy subjects twice at 0 and 24 h.
In the absence of the antagonist, generation of IL-2 by
Figure 1. Effects of one addition of adenosine
or the adenosine deaminase inhibitor EHNA on
T-cell generation of cytokines. T cells were
added to wells with adherent anti-CD3  anti-
CD28 antibodies on d 0 after a 10-min preincu-
bation and continued incubation with a single
addition of 0.3 to 10 M adenosine or 10 M
EHNA. Aliquots of supernates were removed on
d 1 (24 h) for IL-2 ELISAs and d 2 (48 h) for
IFN- ELISAs. Bars represent means  sd of
results of studies of T cells from 3 older men
and women and 3 younger matched control
men and women. In the right panel, control
cytokine levels (100%) were 5518  804 pg/ml
IL-2 and 45,326  3519 pg/ml IFN- for older
subjects; 7420  1168 pg/ml IL-2 and 56,775 
3915 IFN- for younger subjects. Ad, adenosine.
P  0.05, *P  0.01, **P  0.001 vs. control.
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activated T cells at 36 h was a mean  sd of 1467  153
pg/ml for older subjects and 3346  611 pg/ml for
younger subjects. With the introduction of 200 nM
SCH58261 at 0 and 24 h, generation of IL-2 by activated T
cells at 36 h was a mean  sd of 1517  282 pg/ml for
older subjects and 2981  201 pg/ml for younger sub-
jects. As there were no significant changes after blocking
the A2A adenosine receptor, endogenous adenosine ap-
pears to have little regulatory effect in either age group. It
also is not possible to attribute the known lower levels of
IL-2 generation by T cells of older than younger healthy
subjects (20–22) to a suppressive effect of endogenous
adenosine.
Effects of adenosine on human T-cell expression of
surface protein antigens
Multiple additions of 1 M adenosine or 10 M EHNA
adenosine deaminase inhibitor resulted in significant
suppression of T-cell surface levels of CD4, CD8, and
CD28 on activated T cells of both younger and older
subjects after 5 d of incubation (Fig. 3). In every
instance, the extent of suppression of these surface
protein antigens was significantly greater for T cells of
younger than older subjects. A greater sensitivity to
adenosine of the higher levels of CD28 expression by T
cells of younger than older subjects was supported by
Figure 2. Effects of multiple additions of aden-
osine or the adenosine deaminase inhibitor
EHNA on T-cell generation of cytokines. Proce-
dural protocol was the same as in Fig. 1, except
that adenosine and EHNA adenosine deami-
nase inhibitor were added to T cells on d 0, 1,
and 2, with removal of aliquots of supernates at
36 h for IL-2 ELISAs and at 56 h for IFN-
ELISAs. Bars represent means  sd of results of
studies of T cells from 3 older men and women
and 3 younger matched control men and
women. Control IL-2 levels (100%) were 1153 
485 pg/ml for T cells of older subjects and
1773  609 pg/ml for younger subjects; control
IFN- levels (100%) were 35,104  6149 pg/ml
for T cells of older subjects and 36,426  12,585
pg/ml for younger subjects. P  0.05, *P 
0.01 vs. control.
Figure 3. Effects of multiple additions of aden-
osine or the adenosine deaminase inhibitor
EHNA on T-cell expression of surface protein
antigens. Adenosine (1 M) and the adenosine
deaminase inhibitor EHNA were added to T
cells on d 0 (with a 10-min preincubation
before addition to adherent anti-CD3 antibod-
ies), 2 and 4. On d 5, T cells were harvested,
washed, and labeled for flow cytometric assess-
ment of expression of CD28 and CD39 sepa-
rately on the CD4 and CD8 subsets. Bars repre-
sent means  sd of results of studies of T cells
from 2 older men and women (n4) and 2
younger matched control men and women
(n4). Mean  sd fluorescence intensity of
expression of CD28 by control (100%) CD4 T
cells and CD8 T cells, respectively, was 673  59
and 756  32 for younger subjects and 409  18
and 475  34 for older subjects (P0.0001 for
young vs. old groups in both subsets). Mean 
sd fluorescence intensity of expression of CD39
by control (100%) CD4 T cells and CD8 T cells,
respectively, was 265  46 and 264  17 for
younger subjects and 163  18 and 150  12 for
older subjects (P0.05 for young vs. old groups in both subsets). Symbols at tops of bars indicate statistically significant
difference vs. corresponding control; symbols next to horizontal arrowheads indicate difference between bars of that set. P 
0.05, *P  0.01, #P  0.001.
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findings of the effects of similar multiple additions of
0.1 M adenosine over 5 d to stimulated cultures of
CD8 T cells from a subgroup of these subjects. CD28
expression was suppressed by a mean  sd of 28  5%
for CD8 T cells of younger subjects (P0.01), but only
by an insignificant 7  4% for those of older subjects
(n3 young-old pairs). This differential sensitivity may
reflect the chronic accommodation of T cells from
older subjects to higher levels of adenosine than those
usually experienced by the T cells from younger sub-
jects and the higher baseline levels of CD28 expression
by T cells of younger than older subjects (Fig. 3
legend).
In contrast, highly significant adenosine suppression
of expression of CD39, the enzyme that converts ATP to
AMP, was only seen in CD4 and CD8 T cells from older
subjects. Activated T-cell expression of CD73, the en-
zyme that converts AMP to adenosine, was the same in
young and old subjects at respective mean  sd fluo-
rescence intensity levels of 53  11 and 51  12
(n5/group). Expression of CD73 by activated T cells
also was not altered by 48 h of incubation with 10 M
adenosine plus 10 M EHNA, with mean fluorescence
intensity levels of 48  10 for younger and 50  11 for
older subjects. Thus, it seems unlikely that the higher
levels of adenosine generated by T cells of older than
younger subjects are attributable to lower feedback
suppression of CD39 activity by endogenous adenosine.
The greater sensitivity to suppression by adenosine of
expression of some immunologically functional surface
protein antigens than generation of major immune
cytokines suggests a potential rank order of importance
of endogenous adenosine in regulation of diverse T-cell
functions.
Three concentrations of the A2A adenosine receptor
agonist CGS21680 were employed in similar studies
designed to confirm the specificity of suppression of
T-cell surface protein antigens by the adenosine system.
By d 5, multiple additions of 100 nM CGS21680 signif-
icantly suppressed expression of CD4 and CD8, as well
as CD28, on CD4 and CD8 T cells of both younger and
older subjects (Fig. 4). At 20 and 40 nM, CGS21680
significantly suppressed expression of CD8 by T cells of
younger, but not older, subjects and had no effect on
CD4 expression by either group of subjects. At 40 nM,
CGS21680 significantly suppressed expression of CD28
by CD4 and CD8 T cells of younger subjects, with only
marginal reductions in CD28 expression by these sets of
T cells of older subjects. At 20 nM, CGS21680 only
substantially suppressed expression of CD28 by CD8 T
cells of younger subjects (Fig. 1, right panel). As for
adenosine and EHNA, major suppression of CD39 by
all concentrations of CGS21680 was evident only for
CD4 and CD8 T cells of older subjects and was signifi-
cantly greater in extent for the T cells of older than
younger subjects, even in the 3 instances in which it was
significant for the latter group.
CD28 is a T-cell coreceptor for specific surface pro-
teins of antigen-presenting cells and thereby functions
with the T-cell antigen receptor to promote T-cell
functional activation. The level of expression of CD28
by T cells of older subjects is lower than that by T cells
of younger subjects, and this deficiency is considered
one basis for relatively lower activation responses to
antigens of T cells from older subjects (23). To exam-
ine the possibility that higher levels of endogenous
adenosine are, in part, responsible for the relatively
decreased level of expression of CD28 by T cells of
older subjects, T cells from both age groups were
incubated without and with adherent anti-CD3 antibod-
ies for 5 d, and some suspensions received the selective
A2A adenosine receptor antagonists SCH58261 (Ki1.3
nM) or ANR94 (Ki46 nM) on d 0, 2, and 4. For
unstimulated CD4 T cells, CD28 expression was signif-
icantly lower for those of older than younger subjects,
as expected, and this deficiency was corrected by antag-
onizing the A2A adenosine receptor with SCH58261
(Table 2). Stimulation increased CD28 levels in CD4 T
Figure 4. Effects of multiple additions of the
A2A adenosine receptor agonist CGS21680 on
T-cell expression of surface protein antigens.
Protocol is the same as in Fig. 3, including the
number of subjects, with the addition of 3
concentrations of CGS21680 on d 0, 2, and 4,
and labeling of the harvested T cells on d 5.
Symbols at tops of bars indicate statistically
significant difference vs. corresponding control;
symbols next to horizontal arrowheads indicate
difference between bars of that set. P  0.05,
*P  0.01, #P  0.001.
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cells of both age groups significantly (P0.01) and the
lower expression of CD28 by stimulated CD4 T cells
of older than younger subjects was corrected by
SCH58261. However, this increment was not statistically
significant due to high variability of the data. For
unstimulated CD8 T cells of older subjects, SCH58261
increased the level of expression of CD28 significantly
(Table 2). In stimulated CD8 T cells of older subjects,
the baseline expression of CD28 was significantly lower
than that for younger subjects, and SCH58261 in-
creased significantly their level of expression of CD28.
In contrast, neither 100 nor 300 nM A3 receptor
antagonist 2-phenyl-amino-N6-endo-norbornyladenine
(Ki37 nM) had any restorative effect on depressed
levels of CD28 in T cells of older subjects (n3 pairs,
data not shown). In studies of 3 other older subjects,
the similarly selective but structurally distinct and less
potent A2A adenosine receptor antagonist ANR94 also
increased T-cell expression of CD28. For these older
subjects, augmentation of CD28 expression (mean
sd) by 460 nM ANR94 was 147  27% (P0.038) of the
untreated control for CD4 T cells and 128  12%
(P0.0154) of control for CD8 T cells. No significant
change in expression of CD28 was evoked by 460 nM
ANR94 in CD4 T cells or CD8 T cells from the younger
subjects (respective means relative to untreated con-
trols of 96 and 107%).
Flow cytometric quantification of T-cell expression
of A2A adenosine receptors showed mean  sd
fluorescence intensity levels on unstimulated and
activated CD4 T cells of 0.73  0.48 and 24  6.2,
respectively, for older subjects (n6) and 2.4  1.4
and 22  9.0 for younger subjects (n4). The
corresponding values for A2A adenosine receptors on
unstimulated and activated CD8 T cells were 1.48 
1.01 and 48  11, respectively, for older subjects and
1.0  0.43 and 29  20 for younger subjects. T-cell
activation thus very significantly increases expression
of A2A receptors on both subsets of T cells from
younger and older subjects. Only the difference
between A2A receptor levels on activated CD4 and
CD8 T cells in older subjects was significant
(P0.0007). Thus, the adenosine-A2A receptor medi-
ator system is a contributor to decreased levels of
expression of CD28 by T cells of older subjects, but
this age-dependent difference appears to be attribut-
able to higher concentrations of adenosine and/or
enhanced postreceptor signaling in the older sub-
jects and not to higher levels of A2A receptor expres-
sion.
Effects of adenosine on human T-cell chemotaxis
Chemotactic responses of T cells from both older and
younger subjects to the chemokine CCL21, which is a
critical mediator of normal translymphoid tissue traf-
ficking, were suppressed significantly by 0.3 M and 1
M adenosine, and by increases in adenosine levels
elicited by the adenosine deaminase inhibitor EHNA
(Fig. 5). For 1 M adenosine and EHNA, this suppres-
sion was significantly greater for T cells of younger than
older subjects. As for the greater effects of adenosine
on CD28 expression by T cells of younger than older
subjects (Figs. 3 and 4), it is presumed that here, again,
it is attributable to accommodation of the T cells from
older subjects to a chronically higher level of endoge-
nous adenosine. The significant suppression of T-cell
chemotaxis by 0.3 M adenosine, which did not alter
either cytokine generation (Figs. 1 and 2) or expression
of surface protein antigens (Figs. 3 and 4 and text),
further supports the possibility that there is a rank
order of susceptibility of diverse T-cell functions to
adenosine immunoregulation.
Chemotaxis of T cells from older subjects to most
stimuli is lower than that of T cells from younger
subjects. In the present studies, the control (100%)
responses to CCL21 and S1P of T cells from the older
subjects were a mean of 68 to 74% of that of T cells of
the younger subjects. To assess a chemotactic suppres-
sive role for higher endogenous concentrations of
adenosine in the extracellular fluid of T cells from
older subjects, optimally active concentrations of the
A2A receptor antagonists SCH58261 and ANR94 were
added to the T-cell suspensions before their introduc-
tion into chemotactic chambers. Chemotactic re-
TABLE 2. Effects of adenosine A2A receptor antagonist SCH58261 on human T-cell expression of
CD28 coreceptor
Age group TCR stimulation SCH58261 (20 nM)
Mean fluorescence intensity
CD4 T cells CD8 T cells
Young 
 0 189  44 191  42
Young 
  171  42 192  38
Old 
 0 125  45* 141  35
Old 
  193  78 220  43#
Young  0 821  327 810  255
Young   735  278 756  246
Old  0 483  222 430  171*
Old   709  247 658  67#
Values are means  sd of results of flow-cytometric analyses of T cells from 3–5 younger and older
healthy subjects. *P  0.05 vs. corresponding young age group; #P  0.05 vs. corresponding group
without SCH58261 incubation; 2-sample t test.
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sponses of T cells from older subjects, but not those
from younger subjects, to CCL21 and S1P were signif-
icantly increased by SCH58261 and ANR94 (Fig. 5). To
evaluate the extent of these increases, the levels of
chemotaxis of the SCH58261-treated and ANR94-
treated T cells from older subjects were recalculated as
a percentage of that of untreated T cells from younger
subjects, yielding a mean of 96% or higher. As these
levels are not significantly different from those of
untreated T cells of younger subjects, the elimination
of adenosine action on the T cells of older subjects by
the A2A receptor antagonists effectively restored their
chemotaxis to a normal level for younger subjects. In
contrast, neither 100 nor 300 nM A3 receptor antago-
nist 2-phenyl-amino-N6-endo-norbornyladenine had
any restorative effect on depressed levels of chemotaxis
of T cells of older subjects (n2 pairs, data not shown).
DISCUSSION
The adenosine mediator system of T cells from younger
and older healthy subjects differed in 3 major respects.
First, T-cell antigen receptor-directed activation of T
cells from older subjects resulted in extracellular fluid
concentrations of adenosine that were 2.5-fold higher
(P0.0001) than those of activated T cells from
younger subjects (Table 1). Thus, normally the T cells
of older subjects respond to antigenic and other stimuli
in an environment of much higher adenosine concen-
trations than those of younger subjects. Further, phys-
iological levels of adenosine in the extracellular fluids
of T-cell regions in the immune system would be in the
50 nM to 1 M range, as was detected for such fluids of
other mammalian tissues (8), and not at the 5 to 25 M
concentrations employed in most other studies of aden-
osine effects on lymphocytes and other immune cells
(9–12). Even the introduction of an adenosine deami-
nase inhibitor known to prevent degradation of aden-
osine by lymphocytes raised the extracellular fluid
concentrations of adenosine only to 0.3 M (Table
1). When adenosine concentrations in cultures of T
cells were raised to 0.3, 1, 3, or 10 M by a single
exogenous addition at the onset of incubation, the
generation of IL-2 and IFN- were significantly sup-
pressed only by the 10 M level (Fig. 1). However, when
the adenosine concentration was raised to 0.3 M
throughout the period of incubation by the presence of
an adenosine deaminase inhibitor, IL-2 generation was
suppressed to a similar extent as that attained by one
addition of 10 M exogenous adenosine. Multiple
additions of exogenous adenosine to maintain a steady
fluid-phase concentration were employed thereafter in
all subsequent studies. This protocol resulted in signif-
icant suppression of generation of IL-2 and IFN- by 3
M adenosine, but again the highest physiological level
of 1 M adenosine had no effect, and there were no
differences between the results for T cells of older and
younger subjects in any of these cytokine studies (Fig.
2). The generation of cytokines by T cells of older and
younger subjects thus is affected little by extracellular
fluid concentrations of adenosine usually achieved in
immune responses, and the substantial inhibition re-
ported previously is attainable only at pharmacological
levels of 5 to 25 M.
The second major difference between T cells of older
and younger subjects was seen in responsiveness to
adenosine of expression of several immunologically
relevant surface protein antigens. For the T-cell subset-
defining antigens CD4 and CD8, both multiple addi-
tions of 1 M adenosine and the 0.3 M level of
endogenous adenosine established by an adenosine
deaminase inhibitor significantly suppressed the ex-
pression of CD4 and CD8 on T cells from all sources,
with significantly greater effects throughout on T cells
of younger than older donors (Fig. 3). Although the
highest employed concentration of the A2A adenosine
receptor agonist CGS21680 very significantly sup-
pressed CD4 and CD8 expression by T cells of older
Figure 5. Effects of adenosine and the A2A adenosine
receptor antagonists SCH58261 (SCH) and ANR94 (ANR) on
T-cell chemotaxis. T cells from 2 older men and women
(n4) and 2 younger matched control men and women were
preincubated for 15 min and then continuously with 0.1, 0.3,
or 1.0 M adenosine, 10 M EHNA, or 20 nM SCH58261 for
4 h of chemotaxis to 50 nM CCL21 or 100 nM S1P. T cells
from 2 older men and 1 old woman (n3) and 2 younger
matched control men and 1 woman similarly were preincu-
bated for 15 min and then continuously with 460 nM ANR94
for 4 h of chemotaxis to 50 nM CCL21 or 100 nM S1P. Bars
represent means  sd of each cluster of responses as a
percentage of the control responses (100%). Mean CCL21
control chemotactic responses for adenosine, EHNA, and
SCH series were 24.6  7.1% of initial T cells for younger
donors and 16.7  3.8% of initial T cells for older donors
(69% of young control group level). Mean CCL21 control
chemotactic responses for ANR series were 31.8  6.5% of
initial T cells for younger donors and 24.7  3.5% of initial T
cells for older donors (68% of young control group level).
Mean S1P control chemotactic responses for SCH and ANR
series were 7.2  1.1% of initial T cells for younger donors
and 5.3  0.6% of initial T cells for older donors (74% of
young control group level). Symbols at tops of bars indicate
statistically significant difference vs. corresponding control;
symbols next to horizontal arrowheads indicate difference
between bars of that set. P  0.05, *P  0.01, #P  0.01.
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and younger donors similarly, only CD8 expression by
T cells of younger subjects was reduced significantly by
the two lower concentrations of the A2A adenosine
receptor agonist (Fig. 4). The result for CD28 expres-
sion was similar, as multiple additions of 1 M adeno-
sine and the 0.3 M level of endogenous adenosine
established by an adenosine deaminase inhibitor signif-
icantly suppressed the expression of CD28 on CD4 and
CD8 T cells from all sources, with significantly greater
effects throughout on T cells of younger than older
donors (Fig. 3). Again, only the lower concentrations of
the A2A adenosine receptor agonist CGS21680 distin-
guished between CD28 expression by T cells based on
subject age, with significantly greater effects for those of
younger subjects (Fig. 4). Whether this greater sensitiv-
ity to adenosine is attributable to higher baseline
expression of CD28, accommodation to a typically
lower level of adenosine in vivo, or another factor has
not yet been examined. It also is possible that adeno-
sine suppresses CD28 in T cells by more than one
mechanism, including down-regulation of expressed
CD28, as in unactivated T cells (Table 2), and preven-
tion of up-regulation of CD28 that follows T-cell anti-
gen receptor-dependent activation. Application of the
A2A adenosine receptor antagonists SCH58261 and
ANR94 confirmed both the role of endogenous aden-
osine and the central involvement of the A2A adenosine
receptor. SCH58261 and ANR94, but not fully active
concentrations of the A3 receptor antagonist 2-phenyl-
amino-N6-endo-norbornyladenine, significantly increased
the depressed levels of expression of CD28 by unstimu-
lated CD4 T cells, unstimulated CD8 T cells, and stimu-
lated CD8 T cells of older subjects (Table 2).
The third major age-dependent difference in effects
of adenosine on T cells was observed in chemotaxis.
Physiological concentrations of 0.3 and 1 M exoge-
nous adenosine, as well as an 0.3 M level of endog-
enous adenosine established by an adenosine deami-
nase inhibitor, significantly suppressed the chemotactic
responses to CCL21 of T cells from younger and older
subjects, with greater effects on those of younger sub-
jects (Fig. 5). The mean control chemotactic response
of T cells from older subjects was significantly lower
than that of T cells from younger subjects, as had been
shown in other studies (17). Antagonism of the A2A
adenosine receptor by SCH58261 or ANR94 signifi-
cantly enhanced the chemotactic responses of T cells
from older but not younger subjects to two different
stimuli (Fig. 5). This level of enhancement by
SCH58261 or ANR94 raised the chemotactic response
of T cells from older subjects to or above that of T cells
from younger subjects and thereby supported the pos-
sibility that adenosine plays a major role in reducing
chemotactic responses of T cells from healthy older
subjects. As cytokine generation by T cells was unaf-
fected by physiological concentrations of adenosine
that significantly altered T-cell expression of surface
protein antigens and T-cell chemotaxis, the endoge-
nous adenosine mediator system clearly has a greater
influence on these latter aspects of T-cell function, as
well as being a more important mediator in normal
immunity of old subjects.
The present findings have several implications for
our understanding of human immunosenescence. T-
cell immune functions as diverse as expression of
functional cell-surface proteins and chemotactic re-
sponses may be significantly reduced by the same
mediator system. Functional abnormalities of T cells in
healthy older subjects that appear to be due to intrinsic
changes from aging may actually result from changes
with aging in the concentrations of regulatory factors or
in the recognition or signaling mechanisms of such
factors. Perhaps most important for our clinical ap-
proaches to human immunosenescence is the realiza-
tion that those abnormalities attributable to alterations
in regulatory mediator systems are potentially revers-
ible pharmacologically, with specific beneficial effects
for host defenses and control of autoimmune reactions.
For more than a decade, selective A2A receptor
antagonists of diverse structures have been investigated
for their beneficial effects in Parkinson’s disease, in-
cluding motor stimulation, as well as reversal of emo-
tional components, such as depression and anxiety
(24). Limited data also suggested possible improve-
ment in cognition by A2A receptor antagonists. In
several animal models simulating aspects of Parkinson’s
disease, A2A receptor antagonists reduced immobility
directly and had antidepressant effects that depended
in part on dopaminergic signals (25, 26). Two types of
selective A2A receptor antagonists now are shown to
restore full expression of surface immune antigens and
reverse the chemotactic deficiency in T cells of older
subjects at concentrations that would be attained when
it is administered for therapy of Parkinson’s disease. It
will be useful to examine other A2A receptor antago-
nists now in advanced clinical trials for Parkinson’s
disease to completely delineate their effects on T-cell
and other immune functional activities. Immunosenes-
cence could become a near-term target for selective A2A
receptor antagonists, in parallel with Parkinson’s dis-
ease and late-life depression.
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